RARE Form 144: Insider sale of 8,135 shares reported

RARE reported an insider sale filing under Form 144.

Rhea-AI Filing Summary

RARE reported an insider sale filing under Form 144. The filing lists proposed sales of Performance Shares: 688 and Restricted Stock: 5,330, both dated 03/01/2024. It also records a sale by KARAH PARSCHAUER of 8,135 common shares on 03/02/2026 for $185,485.61.

Insights

Insider Transactions Expert

Forms show an insider sale and proposed issuer-held share sales.

The filing lists proposed registrations or planned sales of 688 performance shares and 5,330 restricted shares dated 03/01/2024. It separately reports an actual disposition of 8,135 common shares on 03/02/2026 for $185,485.61.

Cash‑flow treatment for the proposed shares and any resale mechanics are not detailed in the excerpt; subsequent filings or transaction confirmations would state settlement method and who receives proceeds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does RARE's Form 144 show about insider sales?

The Form 144 reports an insider sale and planned sales. It records 8,135 common shares sold on 03/02/2026 for $185,485.61, and proposed sales of 688 performance and 5,330 restricted shares dated 03/01/2024.

Who sold shares according to the RARE Form 144?

Karah Parschauer is named as the seller for the reported transaction of 8,135 common shares on 03/02/2026, with an aggregate amount of $185,485.61 shown in the excerpt.

How many performance and restricted shares are listed for potential sale in RARE's filing?

The filing lists 688 performance shares and 5,330 restricted stock, both dated 03/01/2024. The excerpt labels these securities under "Securities To Be Sold."

Does the Form 144 excerpt state who receives proceeds from the sales?

The excerpt does not specify proceeds recipients for the proposed sales. The recorded sale shows an aggregate $185,485.61 amount for 8,135 shares, but payee details are not provided in the excerpt.

Are the listed proposed sales already completed in the RARE filing?

The excerpt separates "Securities To Be Sold" (proposed items dated 03/01/2024) from reported sales. Only the 8,135-share disposition on 03/02/2026 is shown as sold; proposed items appear as planned, not confirmed settled.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 05:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001677455
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ULTRAGENYX PHARMACEUTICAL INC.
SEC File Number	001-36276
Address of Issuer	60 Leveroni Court Novato CALIFORNIA 94949
Phone	(415) 483-8800
Name of Person for Whose Account the Securities are To Be Sold	KARAH PARSCHAUER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6018	128774.97	96629788	03/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2024	Performance Shares	Issuer			688	03/01/2024	Not Applicable
Common	03/01/2024	Restricted Stock	Issuer			5330	03/01/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KARAH PARSCHAUER 60 Leveroni Court Novato CA 94949	Common	03/02/2026	8135	185485.61

144: Remarks and Signature

Remarks
Date of Notice	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Karah Herdman Parschauer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)